Merck (MRK) Likely Out as Potential Suitor for TESARO (TSRO) or Clovis (CLVS) After AstraZeneca Collaboration - Credit Suisse
Credit Suisse analyst Alethia Young said news that Merck (NYSE: MRK) announced a multi-billion dollar PARP joint venture with AstraZeneca ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)